BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · IEX Real-Time Price · USD
82.22
+0.09 (0.11%)
At close: Jul 2, 2024, 4:00 PM
82.00
-0.22 (-0.27%)
After-hours: Jul 2, 2024, 5:16 PM EDT
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $2.47B in the twelve months ending March 31, 2024, with 13.74% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $648.83M with 8.79% year-over-year growth. In the year 2023, BioMarin Pharmaceutical had annual revenue of $2.42B with 15.42% growth.
Revenue (ttm)
$2.47B
Revenue Growth
+13.74%
P/S Ratio
6.32
Revenue / Employee
$726,740
Employees
3,401
Market Cap
15.61B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | 1.70B | 212.84M | 14.27% |
Dec 31, 2018 | 1.49B | 177.57M | 13.52% |
Dec 31, 2017 | 1.31B | 196.79M | 17.62% |
Dec 31, 2016 | 1.12B | 226.96M | 25.50% |
Dec 31, 2015 | 889.90M | 140.61M | 18.77% |
Dec 31, 2014 | 749.28M | 200.80M | 36.61% |
Dec 31, 2013 | 548.49M | 47.76M | 9.54% |
Dec 31, 2012 | 500.72M | 59.37M | 13.45% |
Dec 31, 2011 | 441.36M | 65.09M | 17.30% |
Dec 31, 2010 | 376.27M | 51.61M | 15.90% |
Dec 31, 2009 | 324.66M | 28.16M | 9.50% |
Dec 31, 2008 | 296.49M | 174.91M | 143.86% |
Dec 31, 2007 | 121.58M | 37.37M | 44.38% |
Dec 31, 2006 | 84.21M | 58.54M | 228.06% |
Dec 31, 2005 | 25.67M | 7.03M | 37.70% |
Dec 31, 2004 | 18.64M | 6.54M | 54.06% |
Dec 31, 2003 | 12.10M | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Dec 31, 2000 | 9.71M | 4.41M | 83.28% |
Dec 31, 1999 | 5.30M | 4.11M | 345.38% |
Dec 31, 1998 | 1.19M | -873.92K | -42.34% |
Dec 31, 1997 | 2.06M | 733.28K | 55.11% |
Dec 31, 1996 | 1.33M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Baxter International | 14.89B |
Labcorp Holdings | 12.30B |
Quest Diagnostics | 9.29B |
Illumina | 4.49B |
Waters | 2.91B |
BeiGene | 2.76B |
Genmab | 2.57B |
United Therapeutics | 2.50B |
BMRN News
- 15 days ago - BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health - PRNewsWire
- 25 days ago - BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress - PRNewsWire
- 7 weeks ago - BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV - PRNewsWire
- 2 months ago - New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting - PRNewsWire
- 2 months ago - BioMarin Reports Record Financial Results for the First Quarter 2024 - PRNewsWire
- 2 months ago - BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET - PRNewsWire
- 4 months ago - New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 4 months ago - BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer - PRNewsWire